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-- 
Heart disease in the patient with hypertension is many- Borderline or mild essential hypertension. This hyperdy- 
faceted (l-4). It may be an adaptive response to sustained namic circulation associated with hypertensive disease may 
and protracted pressure overload or it may coexist with an have various expressions. One common manifestation is 
associated disease. It may vary according to the severity of frequently found in patients with borderline (labile) or mild 
the hypertensive vascular disease, the complex- 
ity of the pathophysiologic mechanisms in- 
:kl : e: .e: 
volved or the coexisting problems offered by one . . . . . . j . . . 
or more associated diseases. As a result, the - - 
management of cardiac disease in the patient 
with hypertension is dependent on the nature 
and extent of cardiac involvement and the 
pathophysiologic mechanisms involved. 
This renort provides a review of the variabil- A N N ’ ” E R ’ A R ’ 
ity and extent of the functional involvement of ’ ’ 4 ’ 
the heart in hypertension. It is written with a plea to the 
student, practitioner and investigator of this major clinical 
problem to consider it apart from other diseases associated 
with pressure overload of the left ventricle. The pathogene- 
sis, the involved pathophysiologic mechanisms, the rate of 
development of cardiac involvement and other aspects of 
hypertensive heart disease are different from those of other 
conditions associated with pressure overload (4-6). 
1 9 8 9 
essential hypertension. In these patients, an 
elevated cardiac output, faster heart rate and 
increased myocardial contractility may be the 
pathophysiologic manifestations of early disease 
that involve the same pressor mechanism. In the 
early stage of the disease this may appear to be 
the result of increased adrenergic input to the 
heart, arterioles and venules. but these changes 
may also reflect interactions with the renopres- 
sor or other pressor or modulating systems (1,2). 
Moreover, the elevated cardiac output is not secondary to an 
expanded intravascular (plasma) volume: in fact, plasma 
volume is usually normal or contracted (7,11,12). However, 
the increased output results from peripheral venoconstric- 
tion that redistributes the circulating intravascular volume 
centrally to the cardiopulmonary area, thereby increasing 
venous return (13). Furthermore if autonomic input to the 
heart is inhibited pharmacologically with parasympathetic 
(i.e., atropine) and beta-adrenergic receptor (i.e., pro- 
pranolol) blocking agents, the elevated cardiac output is 
equilibrated with that of normotensive individuals who are 
similarly treated (14,15), thereby demonstrating that the 
so-called normal total peripheral resistance in the untreated 
individual was “inappropriately normal” and actually in- 
creased (7-9). 
Hyperdynamic Heart 
Early in the development of hypertensive heart disease, 
cardiac involvement may be manifested by findings associ- 
ated with a hyperdynamic circulation (4,7-9). These may 
include a faster heart rate, greater cardiac output than 
normal, an increased myocardial contractility with increased 
oxygen consumption and, perhaps, increased circulating 
catecholamines or responsiveness of the myocardial and 
vascular beta-adrenergic receptor sites (610). 
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Thus, this hyperdynamic state is one of a net increase in 
adrenergic input to the cardiovascular system, and it still is 
not known whether this results from increased sympathetic 
outflow from the brain, hyperresponsiveness of beta- 
adrenergic receptor sites, increases in circulating levels of 
catecholamines, adrenergic “drive” mediated by the periph- 
erally circulating or centrally active renopressure system or 
other mechanisms (16). 
“Hyper-beta state.” Another segment of patients with 
hyperdynamic circulation comprises those patients with a 
hyperdynamic beta-adrenergic circulatory state (17,18). 
These patients present clinically with variable cardiovascu- 
lar manifestations that reflect increased adrenergic input to 
the heart and vessels. Thus, in contrast to the foregoing 
group of asymptomatic patients with borderline (labile) or 
mild to moderate essential hypertension, these patients have 
complaints related to excess stimulation of myocardial or 
vascular smooth muscle beta-adrenergic receptor sites. 
These symptoms include a more forceful or rapid heart rate, 
ectopic cardiac (atria1 or ventricular) beats, palpitation in the 
rest or reflexively stimulated (e.g., upright posture or exer- 
cise) state or feelings of flushing, hot flashes, weakness or 
faintness. Physically, the findings may be manifested by 
systolic or systolic and diastolic pressure elevation, faster 
heart rate, systolic ejection type murmur, cardiac dysrhyth- 
mias and flushing (often in the facial or neck and upper 
thoracic areas). The findings in earlier years prompted such 
diagnoses as irritable heart, soldier’s heart, effort syndrome, 
hyperkinetic heart syndrome or neurocirculatory asthma 
(19,20). 
Physiologic&&zgs include a hyperkinetic circulation, as 
outlined previously, slight elevation of circulating catechol- 
amines (not as high as levels associated with those in 
patients having pheochromocytoma) and increased respon- 
siveness of myocardial beta-adrenergic receptor sites to 
infusion of the synthetic beta-adrenergic receptor agonist 
isoproterenol. In fact, intravenous infusion of isoproterenol 
will provoke the symptoms experienced by these patients 
when they are active or assume upright posture (17,18). 
These symptoms may include anxiety attack, hysteric out- 
bursts and accentuation of milder symptoms that would 
ordinarily be associated with beta-adrenergic receptor stim- 
ulation. Moreover, after intravenous administration of a 
beta-adrenergic blocking agent (e.g., propranolol) these 
physiologic and clinical findings will be normalized or pre- 
vented. 
Mitral valve prolapse. A third manifestation of a hyper- 
dynamic circulation may be seen in patients with idiopathic 
mitral valve prolapse syndrome. These findings are not 
unlike those of the previously defined group of patients with 
a “hyper-beta state” except that these patients will also 
demonstrate the physical, clinical and echocardiographic 
findings of mitral valve prolapse (21,22). In addition, they 
may demonstrate the physiologic findings of a hyperkinetic 
circulation, elevated levels of circulating catecholamines 
(not as high as those levels associated with pheochromo- 
cytoma), increased responsiveness of myocardial beta- 
adrenergic receptor sites and aggravation of the mitral valve 
prolapse during isoproterenol infusion (21,22). Reversal of 
the findings and improvement of the prolapsed valve may be 
expected with beta-blocker therapy. 
Thus, these alterations constitute a hyperdynamic heart 
syndrome and patients with these changes may be treated 
best with beta-adrenergic receptor blocking drugs. How- 
ever, if a beta-blocker cannot be prescribed, calcium antag- 
onists, adrenergic inhibitors and angiotensin-converting en- 
zyme (ACE) inhibitors may be used, although clinical 
improvement may not be as clear-cut as with the beta- 
blocking agents. 
Left Ventricular Hypertrophy 
Hemodynamic factors. As hypertension becomes well 
established in patients with essential hypertension, arterial 
pressure rises pari passu with the increasing total peripheral 
resistance, the classic hemodynamic hallmark of hyperten- 
sion (8,9,23). This increased pressure overload imposed on 
the left ventricle results in a structural hypertrophic adapta- 
tion that is generally concentric in nature (24,25). The 
development of left ventricular hypertrophy, however, may 
not be totally explained by hemodynamic pressure overload 
(l-4,26,27). Some patients with hypertension may also have 
a component of volume overload imposed on the left ventri- 
cle by various factors including physiologic volume overload 
associated with prolonged exercise; pathologically induced 
volume overload associated with either volume-dependent 
essential hypertension or other forms of volume-dependent 
secondary forms of hypertension (e.g., renal parenchymal 
disease, steroidal hypertension, primary aldosteronism or 
congestive heart failure) or exogenous obesity (3,4,28-30). 
Nonbemodynamic factors. Still another very important 
and exciting new aspect of the development of left ventric- 
ular hypertrophy relates to specific “nonhemodynamic” 
factors that have been clinically and experimentally associ- 
ated with the development of left ventricular hypertrophy 
(26,27). These findings are supported by clinical observa- 
tions that indicate that height of arterial pressure in itself 
may not be correlated totally with developed left ventricular 
mass or wall thickness. In part, this may be because the 
pressures obtained to relate with mass and wall thickness do 
not reflect the integrated arterial pressures actually occur- 
ring throughout the 24 h period and over a longer term that 
are “seen” hemodynamically by the left ventricle. How- 
ever, there also is increasing evidence (31) to show that 
patient groups matched for level of arterial pressure, sys- 
temic hemodynamics and clinical and demographic features 
have better (or worse) correlations of hemodynamics with 
structural changes associated with left ventricular hypertro- 
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phy. Moreover, hemodynamic indexes are more directly 
related to structural changes in black rather than white (32) 
or male rather than female (33) patients. Experimentally, the 
lack of correlation between arterial pressure and left ventric- 
ular mass has been shown in the laboratory model of 
essential hypertension, the spontaneously hypertensive rat, 
but not in the Goldblatt (two-kidney, one-clip renal) hyper- 
tensive rat (34); and this same dissociation has been shown 
in the male and female spontaneously hypertensive rat 
treated from conception with beta-adrenergic blocking drugs 
(35). 
over, echocardiography has related altered diastolic function 
to these structurally and systolic functional changes associ- 
ated with hypertrophy (25). Furthermore, impaired diastolic 
filling of the left ventricle has also been demonstrated 
functionally by a reduced filling rate of the left ventricle with 
use of echocardiographic (46) and nuclear scintigraphic (47) 
techniques. 
More compelling evidence relating development of’ left 
ventricular hppertrophy to “nonhemodyncrmic” fcrctors may 
be offered by in vitro tissue culture studies (l-5,36,37) that 
demonstrate development of hypertrophy and myocardial 
protein synthesis when norepinephrine, isoproterenol or 
angiotensin II is added to tissue culture. Molecular and 
cellular biologic support for this thesis was offered recently 
(1,37) by the demonstration of the “on switch” for cellular 
events that mediate call growth by proto-oncogenes. (This 
latter subject will be discussed more extensively later.) 
Thus, increasing clinical, physiologic and experimental evi- 
dence is being amassed to alter the long-standing belief 
that hemodynamic events alone are sufficient to explain 
the long-standing structural adaptation of the left ventricle 
to the pressure overload in systemic arterial hypertension 
(and, perhaps in other pressure overload diseases) (38.39). 
Therefore, factors are being identified that stimulate myo- 
cardial (and probably vascular smooth muscle) mechanisms 
that serve as the biologic “transducers” that translate the 
hemodynamic and other pathophysiologic mechanisms of 
hypertensive disease into structural manifestations of left 
ventricular and arteriolar wall thickening and hypertrophy 
(1,38,40,41). 
Left Ventricular Hypertrophy: 
An Independent Risk 
Risk factors in hypertensive disease. Patients with left 
Clinical correlates. Left ventricular hypertrophy in hyper- 
tensive disease may be identified initially by electrocardio- 
graphic (ECG) means using the criteria of left atrial enlarge- 
ment (e.g., increased P wave amplitude or duration or the 
relation of atrial contraction to its depolarization and polar- 
ization processes) (23,42,43). This involvement does not 
reflect atrial disease primarily but the adaptation of the atria 
to the reduced compliance or distensibility of the hypertro- 
phying chamber of the left ventricle as diastolic filling 
becomes impaired (44). Left ventricular hypertrophy may 
also be demonstrated by the more classic chest roentgeno- 
gram and the many ECG criteria that are associated with 
hypertrophy (23). 
ventricular hypertrophy are at increased risk of cardiovas- 
cular morbidity and mortality (48-51). This risk has been 
shown by prospective clinical and population-based as well 
as clinical investigative studies to be independent of that 
increased risk associated with the systolic and diastolic 
pressure elevations observed in the patient with systemic 
arterial hypertension. Although the precise mechanism or 
mechanisms responsible for the increased risk are not 
known. patients with left ventricular hypertrophy demon- 
strate premature sudden and ischemic heart-related death 
(48-50), an increased number of premature ventricular con- 
tractions throughout a 24 h period (52), more runs of 
ventricular tachycardia during a 24 h period (53) and insuf- 
ficiency of absolute and “reserve” arterial blood supply to 
the myocardium (54). This latter coronary artery insuffi- 
ciency may solely reflect the increased myocardial oxygen 
demand offered by the two determinants of left ventricular 
wall tension: the increased (intraventricular) systolic pres- 
sure and the greater left ventricular radius that is produced 
by the elevated arterial pressure and the hypertrophy pro- 
cess necessary to overcome more efficiently the increased 
pressure overload imposed on the chamber (55). Alterna- 
tively, the coronary insufficiency may be produced by an 
inadequate reserve of the coronary blood supply of the 
hypertrophied muscle (56) or by coexisting coronary artery 
disease because the occlusive arterial atherosclerotic pro- 
cess is enhanced by arterial hypertension (57.58). Of course, 
with coexisting hypertension and coronary artery disease, 
both increased oxygen demand and diminished oxygen sup- 
ply are at least additive in the ischemic effects on the 
myocardium in these patients. Other factors that may also be 
related to the increased risk associated with left ventricular 
hypertrophy include fibrous tissue deposition or fatty amy- 
loid infiltration, diabetic vascular disease or other. as yet 
undescribed. possibilities (4.5,59). 
The rc,hocardiogram, howsoever, is a fbr more sensitilv Therapy to reduce risks. Therapy of patients with left 
means for detecting this hypertrophic process. Not only is it ventricular hypertrophy is based on effective and strict 
able to demonstrate increased left ventricular mass and wall control of the elevated arterial pressure with consequent 
thicknesses before these are evident by KG, but also it reduction of the pressure overload (and its attendant in- 
demonstrates the structural analog for atrial enlargement and creased oxygen demands) imposed on the hypertrophied left 
the structural and functional evidence of that hypertrophy as ventricle. Physiologically, this may be achieved by the 
well as of hypertrophy of the right ventricle (25.45). More- beta-adrenergic receptor blocking drugs, calcium antago- 
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nists or angiotensin-converting enzyme inhibitors. However, 
any therapeutic program designed to provide sustained re- 
duction and control of arterial pressure associated with 
sustained essential hypertension will reverse left ventricular 
hypertrophy if the therapeutic program is maintained for a 
sufficient time period. A recent report (60) from the Framing- 
ham study has shown that treated patients will have im- 
proved morbidity and mortality associated with the reversal 
of this hypertrophy. If one agent does not provide effective 
control of pressure, a second agent (including the addition of 
a diuretic) may achieve this goal (61). 
Reversal of Hypertrophy 
It is important to reemphasize that all agents that control 
arterial pressure, if used for a long enough period of time, 
may be expected to reduce left ventricular mass and, hence, 
hypertrophy (1,2). However, certain agents may reverse this 
process more rapidly (within 4 to 12 weeks) in animals with 
experimental hypertension or in patients (1,2,62,63). The 
rapid response has suggested that certain antihypertensive 
agents possess specific nonhemodynamic qualities that may 
also participate in the reversal of the development of hyper- 
trophy and “regression” process (l-6,26,27). 
Hemodynamic versus structural effects of antihypertensive 
agents. Several experimental findings support the thesis that 
nonhemodynamic as well as hemodynamic factors partici- 
pate in the development of as well as the process that 
reduces cardiac mass. These findings have whetted the 
broad clinical and experimental interest in certain groups of 
pharmacologic agents that rapidly reduce cardiac mass. 
Indeed, the clinical studies have led to inferred (but not 
implied) thinking that centrally active adrenergic inhibiting 
agents, angiotensin-converting enzyme inhibitors and cal- 
cium antagonists best “reverse” left ventricular hypertro- 
phy. It is true, as already indicated, that these agents reverse 
the increased mass more rapidly than do certain other 
agents. But, at present, we do not know whether associated 
with the reduced cardiac and vascular wall thickness and 
mass there is a resulting improvement in cardiac and vascu- 
lar function (1). Recent experimental findings have failed to 
confirm the inference and, in fact, show varying findings 
among these pharmacologic agents that reflect a dissociation 
between their hemodynamic and structural effects (64,65). 
Methyldopa and clonidine. The classic agent that has 
reversed the increased mass of left ventricular hypertrophy 
is methyldopa (34,66,67). However, when another centrally 
acting adrenolytic compound (i.e., clonidine) was used to 
produce the identical hemodynamic effects, left ventricular 
mass was not reduced (67). Nevertheless, when the dose of 
clonidine was tripled, producing an agonist effect on periph- 
eral alpha,-adrenergic receptors, which in turn increased 
total peripheral resistance, cardiac mass then became re- 
duced. 
Moreover, recently, similar hemodynamic effects were 
achieved when we employed the same doses of methyldopa 
that were used previously. In these studies (64) we demon- 
strated that the left ventricular mass of both the spontane- 
ously hypertensive rat and the Wistar-Kyoto normotensive 
control rats (without left ventricular hypertrophy) was also 
diminished significantly. Coincident with these reductions in 
left ventricular mass were significant decreases in the mass 
of the nonhypertrophied right ventricle of both rat groups; 
however, aortic mass failed to change. 
Angiotensin-converting enzyme inhibitors. In contrast to 
the changes associated with methyldopa were distinctly 
different findings with two angiotensin-converting enzyme 
inhibitors (68). These agents (cilazapril and CGS-16617) 
reduced the mass of both the hypertrophied left ventricle of 
the spontaneously hypertensive rat and nonhypertrophied 
left ventricle of the Wistar-Kyoto rat but had no effect on 
right ventricular mass. Aortic mass was reduced with both 
agents in the spontaneously hypertensive rat although CGS- 
16617 did not reduce aortic mass in the normotensive Wistar- 
Kyoto rat. Other studies (69) with calcium antagonists 
revealed findings that were still different. In these later 
studies, both nifedipine and nitrendipine reduced the mass of 
the hypertrophied left ventricle of the spontaneously hyper- 
tensive rat but not that of the nonhypertrophied left ventricle 
of the Wistar-Kyoto rat. And, more perplexing, right ven- 
tricular mass increased in the Wistar-Kyoto rat but not in the 
spontaneously hypertensive rat. 
Thus, it seems premature to ascribe changes of reduced 
left ventricular or total cardiac mass to certain classes of 
antihypertensive agents. More precise studies demonstrating 
changes of all cardiac chambers are necessary; and it is also 
important to know the effect of reduced mass on cardiac 
performance and contractility, irritability, and overall risk 
and on whether the reduced mass is simply a reduction in 
muscle mass or a reversal of true hypertrophy. None of 
these answers is available today. Those clinical studies that 
have been reported either show physiologic changes while 
the patients are still receiving therapy or fail to demonstrate 
performance under a pressure or exercise load. 
Effect of reducing left ventricular mass on pumping per- 
formance. We recently reported our experiences of assess- 
ing left ventricular pumping ability before inducing reduc- 
tions in cardiac mass after pharmacologic reduction of mass 
both at the reduced pressures and when pressure was 
increased abruptly by placing a snare around the ascending 
aorta (64,65). Those studies reported with methyldopa (64) 
showed that pumping ability was impaired after mass was 
reduced and this impairment was aggravated by increasing 
pressure. Pumping performance was changed little by cap- 
topril but, when pressure was elevated, performance deteri- 
orated (65). In contrast to these findings with captopril, 
performance actually increased with cilozapril in both 
Wistar-Kyoto and spontaneously hypertensive rats whose 
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left ventricular mass did not change or was reduced (68); an 
improvement in pumping ability was not observed with the 
angiotensin-converting enzyme inhibitor CGS-16617, al- 
though function did not deteriorate. The findings with the 
two calcium antagonists were likewise challenging to reason; 
thus, pumping ability improved whether left ventricular 
mass was reduced in spontaneously hypertensive rats or was 
not reduced in Wistar-Kyoto rats. However. there was no 
improvement or impairment in performance when aortic 
pressure was increased in the spontaneously hypertensive 
rats with reduced left ventricular mass, but performance 
improved in the Wistar-Kyoto rats without reduced mass. 
These findings demonstrated a definite dissociation be- 
tween the structural and hemodynamic effects of certain 
antihypertensive agents in this experimental setting. The 
differences (even in studies using similar pharmacologic 
classes of agents) suggest differences among drugs in their 
action, penetrance into the cardiac myocyte, or on local 
myositic systems affected by these agents (e.g., proto- 
oncogenes, local renin-angiotensin systems, available cal- 
cium ion-protein synthesis interaction or other as yet unde- 
fined effects) (1,21. 
Implications. At this time, it is not known with certainty 
whether pharmacologically this reduction in left ventricular 
mass actually reduces the increased cardiovascular risk 
imparted by the left ventricular hypertrophy. Moreover, we 
also do not know with certainty whether the reduction in left 
ventricular mass or wall thickness represents a true “re- 
versal” of the process of cellular hypertrophy and of the 
increased risk that is associated with left ventricular hyper- 
trophy. 
Nevertheless, one extremely important factor that should 
be stressed is the importance of careful monitoring of serum 
electrolyte levels (particularly potassium) in predisposed 
patients with hypertension, particularly those with left ven- 
tricular hypertrophy. The hypertrophied left ventricle is 
more predisposed to ventricular dysrhythmias (49,52,53), 
and this irritability may be exacerbated if the patient is 
receiving diuretics or digitalis. This consideration is of 
particular relevance if the patient already has congestive 
heart failure (with secondary aldosteronism and hypokale- 
mia or cardiac dysrhythmias). 
Cardiac Failure 
Predisposing factors to cardiac failure. Left ventricular 
failure is the end-stage of hypertensive heart disease, and it 
results from inability of the heart to adapt further to the ever 
increasing pressure overload (3-5). Alternatively, this com- 
plication may be precipitated earlier in the natural history of 
hypertensive heart disease if there is a second, coexisting 
disease that involves the heart (such as atherosclerotic 
coronary artery disease, exogenous obesity or diabetes 
mellitus). Thus. for example. in patients with atherosclerotic 
coronary artery disease, the myocardial ischemia further 
aggravates the performance of the pressure-overloaded left 
ventricle (55). Under these circumstances there is insuffi- 
cient blood supply to satisfy the myocardial oxygen demands 
associated with pressure overload and hypertrophy. And, in 
hypertensive patients with exogenous obesity. the left ven- 
tricle adapts structurally to the pressure overload by con- 
centric chamber hypertrophy; and the volume overload 
associated with obesity provokes an eccentric form of hy- 
pertrophy (30). This “dimorphic” structural adaptation of 
the left ventricle to the dual overload predisposes the obese 
hypertensive patient to premature cardiac failure. 
As with other problems that are associated with diabetes 
mellitus, careful metabolic control of the diabetes as well as 
control of arterial pressure will assure a better overall 
cardiovascular prognosis. Early clinical studies (70) have 
suggested that angiotensin-converting enzyme inhibitors not 
only provide pressure control, but also may reduce renal 
glomerular hydrostatic pressure and consequent hyperfiltra- 
tion with the postulated resultant glomerulosclerosis associ- 
ated with diabetes. These observations remain to be con- 
firmed in ongoing multicenter trials: and, certain calcium 
antagonists (i.e.. diltiazem and nitrendipine) may also have 
similar renal effects (71-73). 
Therapy. In those patients with hypertension-induced 
left ventricular failure, the primary goals of therapy are 
I) control of arterial pressure and the reduction of the left 
ventricular pressure overload; 2) contraction of the volume 
overload associated with congestive heart failure; and 
3) reestablishment of normal electrolyte balance resulting 
from the secondary hyperaldosteronism. Digitalis and di- 
uretics may help to augment the cardiac pumping ability as 
they reduce the left ventricular preload. The newer angioten- 
sin-converting enzyme inhibitors are of particular value in 
this situation by their ability to reduce the increased preload 
and impedance imposed on the left ventricle; and, in doing 
so. they improve cardiac output and the performance of the 
failing heart (70). Should hypokalemia exist before the use of 
the angiotensin-converting enzyme inhibitor (as a result of 
the secondary hyperaldosteronism). and should its correc- 
tion have been attempted by prescribing potassium-retaining 
agents or supplemental potassium compounds, particular 
care and biochemical monitoring must be exercised to assure 
that the angiotensin-converting enzyme inhibitor does not 
provoke a seemingly paradoxical. life-threatening hyperkale- 
mia. If the angiotensin-converting enzyme inhibitor is not 
prescribed (e.g., because of insensitivity to or side effects of 
these agents in the past), other vasodilating drugs that 
reduce arterial pressure may be employed. However, the 
beta-adrenergic receptor blocking agents are contraindicated 
in patients with cardiac failure, and certain calcium antago- 
nists must be used with caution in these patients because of 
their potential negative inotropic effects on the myocardium. 
One final word is in order concerning cardiac failure in 
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patients with hypertension. Occasionally, pressure overload 
may not appear to be severe enough clinically to produce 
cardiac failure. In these patients, the physician should con- 
sider the coexistence of a second disease-particularly 
“silent” myocardial ischemia or infarction, extensive coro- 
nary artery disease or cardiac dysrhythmias. 
Coronary Artery Disease 
Therapy. As already indicated, insufficiency (i.e., inade- 
quacy) of oxygen delivery to the hypertension-hypertro- 
phied myocardium is produced by the increased tension of 
the left ventricle (55). More often than not, however, this 
insufficiency may be associated with coexisting ischemic 
coronary artery disease, which may be on the basis of 
coronary artery spasm or occlusive atherosclerotic disease. 
In any event, when coronary artery disease is associated 
with systemic arterial hypertension, the goal of therapy 
should be control of arterial pressure to reduce the pressure 
overload and thereby diminish the associated oxygen de- 
mand of the myocardium (55). 
strated to protect the patient with a previous myocardial 
infarction; however, the calcium antagonist diltiazem (79) 
may protect patients with a prior “non-Q wave” myocardial 
infarction from a subsequent similar event. 
Angiotensin-converting enzyme inhibitors. Administra- 
tion of an angiotensin-converting enzyme inhibitor may also 
control arterial pressure and the attendant increased oxygen 
demands of the hypertrophied myocardium by reducing total 
peripheral resistance and by maintaining blood flow to the 
kidney (73). This class of antihypertensive agents has not 
been shown to protect the myocardium from a second 
myocardial infarction; however, they have been reported 
(80) to protect the heart of a patient with a recent myocardial 
infarction from subsequent potentially complicating cardiac 
failure. The mechanism for this protection has been ex- 
plained on the basis of so-called remodeling of the infarcted 
left ventricle, perhaps through mechanisms similar to those 
offered for “regression” of left ventricular mass with an- 
giotensin-converting enzyme inhibitors. 
Calcium channel antagonists and beta-adrenergic blockers. 
In those patients with coronary artery spasm, this control of 
arterial pressure may be best achieved with the calcium 
channel antagonists. Under this circumstance, arterial pres- 
sure is controlled through a reduction in total peripheral 
resistance, and the calcium antagonists are also effective in 
relieving the coronary artery spasm (74). This effect may 
also be achieved with the beta-adrenergic receptor blocking 
agents or the angiotensin-converting enzyme inhibitors. By 
reducing pressure and heart rate (and, hence, the so-called 
double product, the product of systolic pressure and heart 
rate), the beta-blockers reduce the oxygen demand of the 
myocardium and, as a result, angina pectoris may be re- 
lieved. Simply because the beta-blockers reduce cardiac 
output and therefore increase the calculated total peripheral 
resistance, there is no reason to exclude these agents from 
the treatment of patients with coronary artery disease. The 
beta-blockers do not increase vascular resistance in every 
regional organ circulation; in fact, they may be associated 
with an unchanged (or even slightly higher) renal blood flow 
and a reduced renal vascular resistance in patients with 
hypertension (75,76). However, should these agents fail to 
control arterial pressure adequately, a calcium antagonist 
may be substituted or added to the overall treatment pro- 
gram (61). 
Frequently, the physician may wish to maintain therapy 
with the beta-adrenergic receptor blocking drug because of 
its myocardial protective effect. Beta-adrenergic blocking 
agents (exclusive of those with intrinsic sympathomimetic 
activity) have been shown to protect the patient with a 
previous myocardial infarction from developing a subse- 
quent infarction and to have an antiarrhythmic effect (77,78). 
In general, the calcium antagonists have not been demon- 
Conclusion 
Any patient with hypertension has hypertensive heart 
disease. By virtue of the elevated pressure, there is a greater 
oxygen demand of the left ventricle and the heart must have 
adapted structurally and functionally to the increased work 
load. Effective control of arterial pressure not only assures 
improved overall morbidity and mortality from hypertension 
but may even prevent further development of the disease 
and its associated complications. 
Whether reversal of left ventricular hypertrophy reduces 
its independent risk of cardiovascular morbidity and mortal- 
ity is not yet known, but experience and common sense 
dictate that early and vigorous blood pressure control is 
indicated in all patients with hypertension whether or not 
hypertrophy is present. Moreover, this aggressive antihyper- 
tensive therapeutic approach is also indicated with other 
associated cardiac diseases that complicate hypertension. 
References 
I. Frohlich ED. The first Irvine H. Page lecture: the mosaic of hypertension: 
past, present, and future. J Hypertens 1988:6(suppl 4):S2-II. 
2. Frohlich ED. The heart in hypertension: unresolved conceptual chal- 
lenges. Hypertension 1988;l l(suppl 1):1-19-I-24. 
3. Frohlich ED. The heart in hypertension. In: Genest J, Kuchel 0, Hamet 
P, Cantin M, eds. Hypertension: Physiopathology and Treatment. 2nd ed. 
New York: McGraw-Hill. 1983:791-810. 
4. Frohlich ED. The heart in hypertension. In: Rosenthal J, Chobanian AV, 
eds. Arterial Hypertension. 2nd ed. Springer-Verlag (in press). 
5. Frohlich ED. Cardiac hypertrophy: stimuli and mechanisms. In: Sleight 
P, ed. Scientific Foundations of Cardiology. London: William Heinemann 
Medical Books, 1983: 182-90. 
6. Frohlich ED. Hemodynamics and other determinants in development of 
left ventricular hypertrophy: conflicting factors in its regression. Fed Proc 
1983:42:2709-15. 
JACC Vol. 14. No. 7 FROHLICH 1593 
December 1989: 1587-91 CARDIAC DISEASES AND HYPERTENSION 
7. 
8. 
9. 
IO. 
Il. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
Frohlich ED, Kozul VJ. Tarazi RC, Dustan HP. Physiological compari- 
son of labile and essential hypertension. Circ Res 1970:27:55-69. 
Frohlich ED. Hemodynamic factors in the pathogenesis and maintenance 
of hypertension. Fed Proc 1982:41:2400-8. 
Frohlich ED. Hemodynamics of hypertension. In: Genest J. Koiw E. 
Kuchel 0, eds. Hypertension: Physiopathology and Treatment. New 
York: McGraw-Hill, 1977: 15-49. 
Messerli FH. de Carvalho JG. Mills NL. Frohlich ED. Renal artery 
stenosis and polycystic kidney disease. Arch Intern Med 1978:138:1282-3. 
Tarazi RC, Frohlich ED, Dustan HP. Plasma volume in men with 
essential hypertension. N Engl J Med 1968;278:762-5. 
Julius S, Pascual AV, Reilly K, London R. Abnormalities of plasma 
volume in borderline hypertension. Arch Intern Med 1971 :l27: 1169. 
Ulrych M, Frohlich ED, Dustan HP, Page 1H. Cardia output and 
distribution of blood volume in central and peripheral circulations in 
hypertensive and normotensive man. Br Heart J 1969:31:.(70-4. 
Julius S, Pascual AV. London R. Role of parasympathetic inhibition in 
the hyperkinetic type of borderline hypertension. Circulation 1971:44: 
413-8. 
Frohlich ED, Pfeffer MA. Adrenergic mechanisms in human and SHR 
hypertension. Clin Sci Mol Med 1975;48:25s-38s. 
Julius S. Weder AB. Brain and the regulation of blood pressure: a 
hemodynamic perspective. Clinic Hypertens 1989;Al I(suppl I): l-19. 
Frohlich ED. Dustan HP, Page IH. Hyperdynamic beta-adrenergic circu- 
latory state. Arch Intern Med 1966:117:6lC9. 
Frohlich ED. Tarazt RC, Dustan HP. Hyperdynamic beta-adrenergic 
circulatory state: increased beta receptor responsiveness. Arch Intern 
Med 1969:123: l-7. 
Frohlich ED. Beta-adrenergic receptor blockage in the treatment of 
essential hypertension. In: Strauer BC. ed. The Heart in Hypertension. 
New York: Springer-Verlag. 1981:53-71. 
Boudoulas H, Reynolds JC, Mazzaferri E. Wooley CF. Mitral valve 
prolapse syndrome: the effect of adrenergic stimulation. J Am Coll 
Cardiol 1983:2:638-44. 
De Carvalho JG. Messerli FH, Frohlich ED. Mitral valve prolapse and 
borderline hypertension. Hypertension 1979:1:518-22. 
Boudoulas H. Reynolds JC. Mazzaferri E, Wooley CF. Metabolic studies 
in mitral valve prolapse syndrome: aneuroendocrine-cardiovascular pro- 
cess. Circulation 1980;61: 1200-5. 
Frohlich ED. Tarari RC. Dustan HP. Clinical-physiological correlations 
in the development of hypertensive heart disease. Circulation 1971~44: 
446-55. 
Linzbach AJ. Heart failure from the point of view of quantitative 
anatomy. Am J Cardiol 1960;5:370-82. 
Dunn FG, Chardrartna P. de Carvalho JG. Basta LL. Frohlich ED. 
Pathophysiologic assessment of hypertensive heart disease with echocar- 
diography. Am J Cardiol 1977;39:789-95. 
Frohlich ED. Tarari RC. Is arterial pressure the sole factor responsible 
for hypertensive cardiac hypertrophy? Am J Cardiol 1979:44:959-63. 
Tarazi RC. Frohlich ED. Is reversal of cardiac hypertrophy a desirable 
goal of antihypertensive therapy‘? Circulation 1987:75:113-7. 
Tardzi RC. Hemodynamic role of extracellular fluid in hypertension. Circ 
Res 1976;38(suppl 2):73-83. 
Tarari KC. Dustan HP. Frohlich ED. Gifford RW Jr. Hoffman GC. 
Plasma volume and chronic hypertension: relationship to arterial pressure 
levels in different hypertensive diseases. Arch Intern Med 1970;1?5:835- 
42. 
Frohlich ED. Messerli FH, Reism E, Dunn FG. The problem of obesity 
and hypertension. Hypertension 1983:5:71-X. 
Messerli FH. Sundgaard-Riise K. Ventura HO. Dunn FG. Oigman W. 
Frohlich ED. Clinical and hemodynamic determinants of left ventricular 
dimensions. Arch Intern Med 1984:144:477-81. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
46. 
47. 
48. 
49. 
SO. 
51. 
52. 
Dunn FG. Oigman W, Sundgaard-Riise K. et al. Racial differences in 
cardiac adaptation to essential hypertension determined by echocardio- 
graphic indexes. J Am Coll Cardiol 1983;1:1348-51. 
Messerli FH. Garavaglia GE. Schmieder RE, Sundgaard-Riise K, Nunez 
BD. Amodeo C. Disparate cardiovascular findings in men and women 
with essential hypertension. Ann Intern Med 1987;107: 158-61. 
Kuwajima I. Kardon MB. Pegram BL. Sesoko S. Frohlich ED. Regres- 
sion of left ventricular hypertrophy in two-kidney, one clip Goldblatt 
hypertension. Hypertension 1982:4: 113-8. 
Messerli FH. Ventura HO, Reisin E. et al. Borderline hypertension and 
obesity: two prehypertensive states with elevated cardiac output. Circu- 
lation 1982;66:55-60. 
Khairrallah PA. Robertson AL. Davilla D. Effects of angiotensin II on 
DNA, RNA and protein synthesis. In: Genest J, Koiw E. eds. Hyperten- 
sion. New York: Springer-Verlag. 1972:212-20. 
Starksen NF, Simpson PC, Bishopric N. et al. Cardiac myocyte hyper- 
trophy is associated with c-myc proto-oncogene expression. Proc Natl 
Acad Sci USA 1986;83:834&50. 
Frohlich ED. An epilogue: on target-organ involvement in essential 
hypertension based on presented concepts and discussions. Am J Cardiol 
1987:60:1271-321. 
Schmieder RE. Frohlich ED, Messerli FH. Pathophysiology of hyperten- 
sion in the elderly. In: Abrams WB. Frohlich ED, eds. Cardiology Clinics, 
Vol 4. Philadelphia: WB Saunders, 1986:235-43. 
Dzau VJ. Gibbons GH. Autocrine-paracine mechanisms of vascular 
myocytes in systemic hypertension. Am J Cardiol 1987;60:99-103. 
Re RN. Cellular mechanisms of growth in cardiovascular tissue. Am J 
Cardiol 1987:6O(suppl 1):15&6l. 
Dustan HP. Frohlich ED, Geller RG. et al. Current research and 
recommendations from the task force subgroups on therapeutics, preg- 
nancy. obesity. Vol. 9. Report of the Hypertensive Task Force. Wash- 
ington. D.C.: NIH publication no. 79-1631. 1979. 
Messerli FH. Aristimutio GG. Dreslinski GR. et al. Effect of acute 
alpha-adrenergic blockage on systemic hemodynamics, circulating cate- 
cholamine levels, and reflexive cardiovascular changes. In: Les Alpha- 
Bloquantc: Pharmdcoiogie Experimentale et Clinique. Masson, Paris: 
19X1:259-62. 
Braunwdld E, Frahm CF. Studies on Starling’s law of the heart. 
IV. Observations in the hemodynamic functions of the left atrium in man. 
Circulation 1961:244:633-42. 
Nunez BD. Messerli FH, Garavaglia GE. Schmieder RE, Amodeo C. 
Frohlich ED. Right ventricular adaptation in obese hypertensive patients 
(abstr). J Am Coil Cardiol 1987:9:244A. 
Dreslinvki GR. Frohlich ED, Dunn FG, Messerli FH. Suarez DH, Reisin 
E. Echocardiographic diastolic ventricular abnormality in hypertensive 
heart disease: atrial emptying index. Am J Cardiol 1981:47:1087-90. 
lnouye 1. Massie B. Loge D. et al. Abnormal left ventricular filling: an 
early finding in mild to moderate systemic hypertension. Am J Cardiol 
198453: I206 
Kannel WB. Gordon T. Offutt D. Left ventricular hypertrophy by 
electrocardiogram: prevalence, incidence and mortality in the Framing- 
ham study. Ann Intern Med 1969;71:89-105. 
Frohlich ED. Potential mechanisms explaining the risk of left ventricular 
hypertrophy. .4m J Cardiol 1987:59:9lA-7A. 
Sava_ee DD. Garrison RJ. Kannel WB, et al. The spectrum of left 
ventrtcular hypertrophy in a general population sample: the Framingham 
study. Circulation 1987:25:1623. 
Levy D. Garrison RJ, Savage DD, Kannel WB. Castelli WP. Left 
ventricular mass and incidence of coronary heart disease in an elderly 
cohort: the Framingham heart study. Ann Intern Med 1989;l lO:lOl-7. 
Messerli FH. Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hyper- 
tension and sudden death: increased ventricular ectopic activity in left 
ventricular hypertrophy. Am J Med 1984:77:18-22. 
1594 FROHLICH 
CARDIAC DISEASES AND HYPERTENSION 
JACC Vol. 14, No. 7 
December 1989: 1587-94 
53. McLenachan JM. Henderson E. Morris KL. Daraie HJ. Ventricular 
arrhythmias in hypertensive left ventricular hypertriphy. N Engl J Med 
1987;317:787-92. 
54 
55. 
56. 
51. 
58. 
59. 
60. 
61. 
62. 
63. 
64. 
65. 
66. 
Pringle SD, Macfarlane PW, McKillop JH, Lorimer AR, Dunn FG. 
Pathophysiologic assessment of left ventricular hypertrophy and strain in 
asymptomatic pateints with essential hypertension. J Am Coil Cardiol 
1989;13:1377-81. 
Dunn FG, Frohhch ED. Hypertension and angina pectoris. In: Yu PN, 
Goodwin JF, eds. Progress in Cardiology, Vol 7. Philadelphia: Lea & 
Febiger, 1978:163-96. 
Harrison DG, Barnes DH, Hitatzka LF, Eastham CL, Kerber RE, 
Marcus ML. The effect of cardiac hypertrophy on the coronary collateral 
circulation. Circulation 1985;71:1135-45. 
Wittels EW, Gotto AM Jr. Atherogenic mechanisms. In: Frohlich ED, ed. 
Pathophysiology: Altered Regulatory Mechanisms in Disease. 3rd ed. 
Philadelphia: JB Lippincott, 1984: 107-18. 
Dustan HP. George Lyman Duff Lecture. Atherosclerosis complicating 
chronic hypertension. Circulation 1974;50:871-9. 
Sen S, Bumpus FM. Collagen synthesis in development and reversal of 
cardiac hypertrophy in spontaneously hypertensive rats. Am J Cardiol 
1979;44:954-8. 
Kannel WB, D’Agostino RB, Levy D, Belanger AJ. Prognostic signifi- 
cance of regression of left ventricular hypertrophy (abstr). Circulation 
1988;78(suppl II):II-89. 
The Joint National Committee on the Detection, Evaluation, and Treat- 
ment of High Blood Pressure: The 1988 Report of the Joint National 
Committee on Detection, Evaluation, and Treatment of High Blood 
Pressure. Arch Intern Med 1988;148:1023-38. 
Frohlich ED. Changes in hypertrophy by treatment in hypertension: 
results of experimental research. In: Kaufmann W, Bonner G, Lang I, 
Meurer KA, eds. Primary Hypertension. Berlin: Springer-Verlag, 1986: 
105-14. 
Frohlich ED. Reversal of target-organ involvement in systemic hyperten- 
sion: a pharmacologic experience. Am J Cardiol 1987;60: 11-21. 
Sasaki 0, Kardon MG, Pegram BL, Frohlich ED. Aortic distensibility 
and left ventricular pumping ability after methyldopa in Wistar-Kyoto and 
spontaneously hypertensive rats. J Vascular Med Biol 1989;1:59-66. 
Natsume T, Kardon MB, Pegram BL. Frohlich ED. Ventricular perfor- 
mance in spontaneously hypertensive rats with reduced cardiac mass. 
Cardiovasc Drugs Ther 1989;3:433-9. 
Sen S, Tarazi RC, Bumpus FM. Reversal of cardiac hypertrophy in renal 
hypertensive rats: medical versus surgical therapy. Am 3 Physiol 1981; 
240:H408-H12. 
67. 
68. 
69. 
70. 
71. 
72. 
13. 
14. 
75. 
76. 
77. 
Pegram BL, Ishise S, Frohlich ED. Effect of methyldopa, clonidine, and 
hydralazine on cardiac mass and haemodynamics in Wistar-Kyoto and 
spontaneously hypertensive rats. Cardiovasc Res 1982;16:40-6. 
Frohlich ED, Sasaki 0. Dissociation of changes in cardiovascular mass 
and performance in converting enzyme inhibitors (abstr). Hypertension 
1989;14:341. 
Frohlich ED, Sasaki 0. Calcium antagonists variably change cardiovas- 
cular mass and improve function in rats (abstr). J Am Coil Cardiol (in 
press). 
Frohlich ED. Angiotension converting enzyme inhibitors: present and 
future. Hypertension 1989;13(suppl 1):1-125-I-30. 
Amodeo C, Kobrin I, Ventura HO, Messerli FH, Frohlich ED. Immediate 
and short-term hemodynamic effects of diltiazem in patients with hyper- 
tension Circulation 1986;73:108-13. 
Isshiki T, Amodeo C, Messerli FH, Pegram BL, Frohlich ED. Diltiazem 
maintains renal vasodilation without hyperhltration in hypertension: 
studies in essential hypertensive man and the spontaneously hypertensive 
rat. Cardiovasc Drugs Ther 1987;1:359-66. 
Grossman E, Oren S, Garavaglia GE, Messerli FH, Frohlich ED. 
Systemic and regional hemodynamic and humoral effects of nitrendipine 
in essential hypertension. Circulation 1988;78: 1394-400. 
McCall D, Walsh RA, Frohlich ED, O’Rourke RA. Calcium entry 
blocking drugs: mechanisms of action, experimental studies, and clinical 
uses. Curr Probl Cardiol 1985;10:7-80. 
Nishiyma K, Nishiyama A, Pfeffer MA, Frohlich ED. Systemic and 
regional blood flow distribution in normotensive and spontaneously 
hypertensive young rats subjected to lifetime beta-adrenergic receptor 
blockage. Blood Vessels 1978;15:333-47. 
Frohlich ED, Messerli FH, Dreslinski GR, Kobrin I. Long-term renal 
hemodynamic effects of nadolol in patients with essential hypertension. 
Am Heart J 1984;108: 1141-3. 
Beta-Blocker Heart Attack Trial Research Group. A randomized trial of 
propranolol in patients with acute myocardial infarction. I. Mortality 
results. JAMA 1982;247:1707-914. 
78. The Norwegian Multicenter Study Group. Timolol-induced reduction in 
mortality and reinfarction in patients surviving acute myocardial infarc- 
tion. N Engl J Med 1981;304:801-7. 
79. Perryman B, Roberts R. Diltiazem Reinfarction Study Group: Diltiazem 
and reinfarction in patients with non-Q-wave myocardial infarction: 
results of a double-blind randomized, multicenter trial. N Engl J Med 
1986:315:423-9. 
80. Pfeffer MA, Pfeffer JM, Steinbert C, Finn P. Survival after an experimen- 
tal infarction: beneficial effects of long-term therapy with captopril. 
Circulation 1985:72:40612. 
